ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.1819dup (p.Thr607fs)

dbSNP: rs587779221
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000074688 SCV000107891 pathogenic Lynch syndrome 2013-09-05 reviewed by expert panel research Coding sequence variation resulting in a stop codon
GeneDx RCV000482414 SCV000566298 pathogenic not provided 2015-04-17 criteria provided, single submitter clinical testing This duplication of one nucleotide in MSH6 is denoted c.1819dupA at the cDNA level and p.Thr607AsnfsX33 (T607NfsX33) at the protein level. The normal sequence, with the base that is duplicated in brackets, is TAAA[A]CAAT. The duplication causes a frameshift, which changes a Threonine to an Asparagine at codon 607, and creates a premature stop codon at position 33 of the new reading frame. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. we consider this variant to be pathogenic.
Ambry Genetics RCV002408571 SCV002710407 pathogenic Hereditary cancer-predisposing syndrome 2021-11-16 criteria provided, single submitter clinical testing The c.1819dupA pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a duplication of A at nucleotide position 1819, causing a translational frameshift with a predicted alternate stop codon (p.T607Nfs*33). This variant was identified in a cohort of 4439 women with ovarian cancer undergoing multigene panel testing at one laboratory (Carter NJ et al. Gynecol Oncol, 2018 12;151:481-488). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Myriad Genetics, Inc. RCV003450932 SCV004185815 pathogenic Lynch syndrome 5 2023-08-15 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.